Cervical Cancer - Pipeline Insight, 2024

This “Cervical Cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Cervical cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cervical Cancer Understanding

Cervical Cancer: Overview

Cervical cancer remains the fourth most common cancer in developing countries. It develops in a woman's cervix (the entrance to the uterus from the vagina) and happens when the cells on your cervix begin to change to precancerous cells. Not all precancerous cells will turn to cancer, but finding these problematic cells and treating them before they can change is critical to preventing cervical cancer. Early stages of cervical cancer don't usually involve symptoms and are hard to detect. The first signs of cervical cancer may take several years to develop. Some symptons of cervical cancer includes: Watery or bloody vaginal discharge that may be heavy and can have a foul odor, Vaginal bleeding after intercourse, between menstrual periods or after menopause, Menstrual periods may be heavier and last longer than normal. Screening with a Pap test can detect most cases of cervical cancer that collects cells from your cervix as well as tests for Liver, kidney, Blood, urine tests, X-rays are also needed. The treatments for cervical cancer are radiation, chemotherapy, surgery, targeted therapy and immunotherapy.

Cervical Cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cervical Cancer pipeline landscape is provided which includes the disease overview and Cervical Cancer treatment guidelines. The assessment part of the report embraces, in depth Cervical Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cervical Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gonorrhoea R&D. The therapies under development are focused on novel approaches to treat/improve Gonorrhoea.

Cervical Cancer Emerging Drugs Chapters

This segment of the Cervical Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cervical Cancer Emerging Drugs

Axalimogene filolisbac: Advaxis Axalimogene filolisbac is a type of cancer vaccine being developed as immunotherapy that attacks HPV-associated cancers such as cervical cancers. It works by alerting the body’s immune system to the presence of cancer, stimulating the body’s natural defenses to attack the cancer. Axalimogene filolisbac is given intravenously and is being developed for the treatment of persistent, recurrent, or metastatic, squamous or non-squamous cell cervical cancer in patients who progress beyond first-li Phase III Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV ne therapy. If licensed, Axalimogene filolisbac will offer a new treatment option for this patientgroup.

Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer. The drug is currently being evaluated in Phase III clinical trial for the treatment of cervical cancer.

AK104: Akeso Cadonilimab (AK104) is a novel, potential next-generation, first-in-class bi-specific PD-1/CTLA-4 immuno-oncology backbone drug independently developed by the Company, and its major indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell cancer and nasopharyngeal carcinoma. The preliminary research data of cervical cancer, gastric cancer and other tumors shows that, as compared with the combination therapy of PD-1 and CTLA-4, Cadonilimab has much lower toxicity and demonstrated promising safety profile and efficacy. In September 2020, National Medical Products Administration (the NMPA) of China has officially accepted the new drug application for the world’s first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and development code: AK104) for the treatment of relapsed or metastatic cervical cancer, which has received priorityreview.

• Durvalumab :AstraZeneca

A drug that binds to the protein PD-L1 to help immune cells kill cancer cells better and is used to treat different types of cancer. Durvalumab is used alone or with other drugs to treat adults with certain types of extensive-stage small cell lung cancer or stage III non-small cell lung cancer. It is also being studied in the treatment of other types of cancer. Durvalumab may block PD-L1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. A Phase III clinical trial is being conducted for durvalumab to treat patients with cervical cancer.

• HLX10:Shanghai Henlius Biotech

HLX10, a novel recombinant humanised anti-programmed cell death protein 1 (PD-1) mAb independently developed by Henlius, has the potential to treat a variety of solid tumours. HLX10 has exhibited better pharmacokinetics, pharmacodynamics properties, favourable safety, tolerability profile and anti-tumor activity in preclinical and early clinical research studies. It is currently being investigated in Phase II stage of development to provide the potential treatment for cervical cancer.

Cervical Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Cervical Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cervical Cancer

There are approx. 70+ key companies which are developing the therapies for Cervical Cancer. The companies which have their Cervical Cancer drug candidates in the most advanced stage, i.e. phase III include, Advaxis.

Phases

This report covers around 70+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cervical Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cervical Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cervical Cancer drugs.

Cervical Cancer Report Insights

• Cervical Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cervical Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cervical Cancer drugs?
• How many Cervical Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cervical Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cervical Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cervical Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Regeneron Pharmaceuticals
• Jiangsu Hengrui Medicine
• Akeso Biopharma
• Celgene/MedImmune
• Henlix Biotech
• Zeria
• Advaxis
• Akeso Biopharma
• AnGes
• Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical
• Valent recombinant vaccine - National Vaccine and Serum Institute
• Xiamen Innovax Biotech
• Genentech
• Celgene/MedImmune
• Bristol-Myers Squibb
• Ono Pharmaceuticals
• InnoMab
• BeiGene
• Agenus/Ludwig Institute for Cancer Research
• EMD Serono
• Merck
• Apollomics
• Immunitor
• Genentech
• Arcus Biosciences
• Guangzhou Gloria Biosciences
• Taiho Pharmaceutical
• Innovent Biologics
• Clovis Oncology
• Janssen
• GlaxoSmithKline
• Iovance Biotherapeutics

Key Products

• Cemiplimab
• Camrelizumab
• AK-104
• Durvalumab
• HLX10
• Serplulimab
• Z 100
• Axalimogene filolisbac
• Cadonilimab
• Human papillomavirus vaccine
• Catequentinib
• Atezolizumab
• Human papillomavirus recombinant vaccine nonavalent
• Nivolumab
• Nimotuzumab
• Tislelizumab
• Balstilimab
• Bintrafusp alfa
• Geptanolimab
• Cervical cancer vaccine
• Tiragolumab
• Zimberelimab
• Ipilimumab biosimilar
• Rucaparib
• Niraparib
• Autologous tumour infiltrating lymphocytes

This product will be delivered within 1-3 business days.